INT72539

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 12
Disease Relevance 4.98
Pain Relevance 8.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Sorbs1) transport (Sorbs1) plasma membrane (Sorbs1)
cytoskeleton (Sorbs1) nucleus (Sorbs1) cytoplasm (Sorbs1)
Anatomy Link Frequency
muscle 1
neurons 1
fat cells 1
ventral 1
Sorbs1 (Mus musculus)
Pain Link Frequency Relevance Heat
qutenza 222 100.00 Very High Very High Very High
Action potential 18 100.00 Very High Very High Very High
Calcitonin gene-related peptide 384 99.96 Very High Very High Very High
Nerve growth factor 400 99.70 Very High Very High Very High
dorsal root ganglion 48 99.50 Very High Very High Very High
antinociception 8 99.36 Very High Very High Very High
Neuropeptide 44 98.24 Very High Very High Very High
Kinase C 6 97.96 Very High Very High Very High
narcan 8 94.72 High High
Thermal hyperalgesia 12 94.28 High High
Disease Link Frequency Relevance Heat
Pneumonia 90 100.00 Very High Very High Very High
Ganglion Cysts 292 99.50 Very High Very High Very High
Obesity 98 98.64 Very High Very High Very High
Nociception 40 96.20 Very High Very High Very High
Hyperalgesia 28 94.28 High High
Injury 93 93.20 High High
Emergencies 9 92.68 High High
Pain 23 91.08 High High
Sepsis 54 88.16 High High
INFLAMMATION 127 87.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Given i.c.v., both CPZ and RR caused discrete antinociception in the FM (both phases), while producing graded inhibition of CAP.
Gene_expression (producing) of CAP associated with antinociception and qutenza
1) Confidence 0.78 Published 1997 Journal Neurosci. Lett. Section Abstract Doc Link 9389599 Disease Relevance 0.40 Pain Relevance 1.62
mM) on the CAP that was incubated at 30?
Gene_expression (on) of CAP associated with action potential
2) Confidence 0.22 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2952823 Disease Relevance 0.16 Pain Relevance 0.70
We enrolled adults 18 years or older who presented with CAP, as diagnosed by the criteria of Fine et al [17].
Gene_expression (presented) of CAP associated with pneumonia
3) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973976 Disease Relevance 0.82 Pain Relevance 0.15
Older subjects were more likely to have severe CAP upon presentation, as evidenced by greater proportion of older adults with a Pneumonia Severity Index score ?
Gene_expression (have) of CAP associated with pneumonia
4) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973976 Disease Relevance 0.33 Pain Relevance 0
Older subjects were more likely to have severe CAP upon presentation, as evidenced by greater proportion of older adults with a Pneumonia Severity Index score ?
Gene_expression (severe) of CAP associated with pneumonia
5) Confidence 0.16 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2973976 Disease Relevance 0.33 Pain Relevance 0
Intriguingly, whereas many growth factors trigger the activation of PI3K, AKT, and PKC in many cell types, aspects of the c-Cbl–CAP pathway, including the tyrosine phosphorylation and the expression of CAP, seem to be unique to muscle and fat cells [144].
Gene_expression (expression) of CAP in fat cells associated with kinase c and obesity
6) Confidence 0.06 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2911604 Disease Relevance 0.45 Pain Relevance 0.12
Thus, the amplitude and shape of ventral column CAPs from Claudin 11–null mice are similar to controls and differ only by an increase in CAP duration (Fig.
Gene_expression (duration) of CAP in ventral
7) Confidence 0.05 Published 2008 Journal The Journal of Cell Biology Section Body Doc Link PMC2592840 Disease Relevance 0 Pain Relevance 0.11
In accordance with this increased CAP sensitivity, NGF increases the expression of the CAP- and noxious heat-sensitive ion channel vanilloid receptor type 1 (TRPV1) through the ras/p38 MAP kinase signaling pathway, thereby promoting thermal hyperalgesia [25,26].
Gene_expression (expression) of CAP associated with nerve growth factor, qutenza and thermal hyperalgesia
8) Confidence 0.04 Published 2005 Journal BMC Neurosci Section Body Doc Link PMC548274 Disease Relevance 0.78 Pain Relevance 1.39
BDNF also enhanced the ability of CAP to evoke CGRP release; however, the effect was only seen at the 100 ng/ml concentration.
Gene_expression (evoke) of CAP associated with qutenza and calcitonin gene-related peptide
9) Confidence 0.04 Published 2005 Journal BMC Neurosci Section Body Doc Link PMC548274 Disease Relevance 0 Pain Relevance 1.40
In cultured DRG neurons, GDNF increases CAP sensitivity and TRPV1 expression [16,26] and increases neuropeptide content [16].
Gene_expression (sensitivity) of CAP in neurons associated with dorsal root ganglion, qutenza and neuropeptide
10) Confidence 0.04 Published 2005 Journal BMC Neurosci Section Body Doc Link PMC548274 Disease Relevance 0.83 Pain Relevance 1.61
DCS conducted the intitial CAP-evoked CGRP release study.
Gene_expression (conducted) of CAP associated with qutenza and calcitonin gene-related peptide
11) Confidence 0.03 Published 2005 Journal BMC Neurosci Section Body Doc Link PMC548274 Disease Relevance 0.43 Pain Relevance 0.91
Intriguingly, whereas many growth factors trigger the activation of PI3K, AKT, and PKC in many cell types, aspects of the c-Cbl–CAP pathway, including the tyrosine phosphorylation and the expression of CAP, seem to be unique to muscle and fat cells [144].
Gene_expression (expression) of CAP in muscle associated with kinase c and obesity
12) Confidence 0.02 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2911604 Disease Relevance 0.45 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox